A great day ahead in Waltham, MA at the Madrigal Pharmaceuticals 2024 Patient Advocate Summit. Opening this interactive day with CEO, Bill Sibold’s welcome. Global Liver Institute, European Liver Patients' Association - ELPA, LPI LIVER PATIENTS INTERNATIONAL, Fatty Liver Foundation, NASH kNOWledge, Community Liver Alliance, American Liver Foundation, Midsouth Sober Living, American Association for the Study of Liver Diseases (AASLD), EASL | The Home of Hepatology
Fatty Liver Alliance’s Post
More Relevant Posts
-
📣 There is no approved treatment for Acute-on-Chronic Liver Failure (#ACLF), a life-threatening condition with an extremely high sense of emergency for patients, clinicians, regulators and payers. Our pipeline includes five assets in development to address ACLF and its complications. 📍 We will be present at the #EASL congress to talk about ACLF via 3 events and 2 scientific posters: 🎤 EF CLIF and GENFIT partnership event 🎤 UNVEIL-IT® Investigator Meeting 🎤 ELPA educational training event 📊 Poster #1: blood and peritoneal metabolomics suggest VS-01 actively captures metabolites associated with ACLF 📊 Poster #2: Nitazoxanide directly protects from stress-induced cell death to alleviate liver damage in preclinical models of ACLF 👉 Read more on our Press Release: https://lnkd.in/e5FMvpdy 🎬 See the full ACLF video: https://lnkd.in/ene_QTwV EASL | The Home of Hepatology European Foundation for the Study of Chronic Liver Failure (EF CLIF) European Liver Patients' Association - ELPA #EASLCongress #Hepathology #LiverDisease #MultipleOrganFailures #RareDisease #LiverFailure #Cirrhosis
To view or add a comment, sign in
-
The official journal of the Mexican Association of Hepatology, the Latin American Association for the Study of the Liver, the Canadian Association for the Study of the Liver and the Czech Society of Hepatology
🔬🧬 Explore the latest research from the Annals of Hepatology! Dr. Shi Ouyang and team investigate the role of ZBP1 in hepatocyte pyroptosis during acute liver injury (ALI). Here's a glimpse into their findings: 📚 Title: "ZBP1 promotes hepatocyte pyroptosis in acute liver injury by regulating the PGAM5/ROS pathway" 🔍 Abstract Highlights: - ZBP1 up-regulation 🔝observed in induced hepatocytes - Silencing ZBP1 inhibited NLRP3 inflammasome activation and pyroptosis, while also reducing PGAM5 expression and ROS production. 🧬 Conclusion: ZBP1 plays a crucial role in promoting hepatocellular pyroptosis by modulating mitochondrial damage and ROS release 💥 Stay informed! Read the full study here 👇🏼 https://lnkd.in/gQD5FpmR #Hepatology #LiverInjury #ResearchInsights
To view or add a comment, sign in
-
Nomenclature changes were announced at the 2023 EASL Congress, shifting NASH to metabolic dysfunction-associated steatohepatitis (MASH). This has broader impacts on liver diseases, including reducing stigma, increasing disease awareness, and accelerating drug and biomarker development in hepatology. Learn more about the latest insights and updates from our MASH experts IHEP (International Hepatology Education Program): https://bit.ly/3vLfgJM #AvalereHealth #Hepatology #MedicalScience #MASH #NASH #NAFLD #GLP1
Avalere Health | Trends 2024: Will GLP-1 receptor agonists dominate the MASH therapeutic market?
avalerehealth.com
To view or add a comment, sign in
-
GLP-1 receptor agonists surged in 2023, with a 352% rise in prescriptions. With these treatments reshaping the obesity and diabetes landscape, hepatology experts IHEP (International Hepatology Education Program) ask what the impact could be for metabolic dysfunction-associated steatohepatitis. Learn their insights and find out how the treatment landscape is changing: https://bit.ly/3vLfgJM #AvalereHealth #Hepatology #MedicalInnovation #MASH #NASH #GLP1
Avalere Health | Trends 2024: Will GLP-1 receptor agonists dominate the MASH therapeutic market?
avalerehealth.com
To view or add a comment, sign in
-
GLP-1 receptor agonists surged in 2023, with a 352% rise in prescriptions. With these treatments reshaping the obesity and diabetes landscape, hepatology experts IHEP (International Hepatology Education Program) ask what the impact could be for metabolic dysfunction-associated steatohepatitis. Learn their insights and find out how the treatment landscape is changing: https://bit.ly/3vLfgJM #AvalereHealth #Hepatology #MedicalInnovation #MASH #NASH #GLP1
Avalere Health | Trends 2024: Will GLP-1 receptor agonists dominate the MASH therapeutic market?
avalerehealth.com
To view or add a comment, sign in
-
GLP-1 receptor agonists surged in 2023, with a 352% rise in prescriptions. With these treatments reshaping the obesity and diabetes landscape, hepatology experts IHEP (International Hepatology Education Program) ask what the impact could be for metabolic dysfunction-associated steatohepatitis. Learn their insights and find out how the treatment landscape is changing: https://bit.ly/3vLfgJM #AvalereHealth #Hepatology #MedicalInnovation #MASH #NASH #GLP1
Avalere Health | Trends 2024: Will GLP-1 receptor agonists dominate the MASH therapeutic market?
avalerehealth.com
To view or add a comment, sign in
-
GLP-1 receptor agonists surged in 2023, with a 352% rise in prescriptions. With these treatments reshaping the obesity and diabetes landscape, hepatology experts IHEP (International Hepatology Education Program) ask what the impact could be for metabolic dysfunction-associated steatohepatitis. Learn their insights and find out how the treatment landscape is changing: https://bit.ly/3vLfgJM #AvalereHealth #Hepatology #MedicalInnovation #MASH #NASH #GLP1
Avalere Health | Trends 2024: Will GLP-1 receptor agonists dominate the MASH therapeutic market?
avalerehealth.com
To view or add a comment, sign in
-
Logical from what I understand about aspirin & salicylates.
An aspirin a day keeps the liver Doctor away? “At 6 months, 42.5% of patients on low-dose aspirin had at least a 30% reduction in hepatic fat.” “Given as a once-daily 81-mg dose, the aspirin was safe and well-tolerated during the short study period, they detailed in JAMA with no bleeding events or drug-related serious adverse events (AEs).” Reference: JAMA. 2024;331(11):920-929. doi:10.1001/jama.2024.1215. Barcelona Institute for Global Health (ISGlobal), American Association for the Study of Liver Diseases (AASLD) EASL | The Home of Hepatology Global NASH Council European Liver Patients' Association - ELPA Global Liver Institute #aspirin #masld Kathleen Corey, Perspectum Ltd
Aspirin Cuts Liver Fat in Preliminary MASLD Trial
medpagetoday.com
To view or add a comment, sign in
-
Our hepatology experts, IHEP (International Hepatology Education Program), ask what the impact of GLP-1s could be for metabolic dysfunction-associated steatohepatitis. Read their insights: https://bit.ly/3vLfgJM
Avalere Health | Trends 2024: Will GLP-1 receptor agonists dominate the MASH therapeutic market?
avalerehealth.com
To view or add a comment, sign in
-
Interesting news about aspirin.
An aspirin a day keeps the liver Doctor away? “At 6 months, 42.5% of patients on low-dose aspirin had at least a 30% reduction in hepatic fat.” “Given as a once-daily 81-mg dose, the aspirin was safe and well-tolerated during the short study period, they detailed in JAMA with no bleeding events or drug-related serious adverse events (AEs).” Reference: JAMA. 2024;331(11):920-929. doi:10.1001/jama.2024.1215. Barcelona Institute for Global Health (ISGlobal), American Association for the Study of Liver Diseases (AASLD) EASL | The Home of Hepatology Global NASH Council European Liver Patients' Association - ELPA Global Liver Institute #aspirin #masld Kathleen Corey, Perspectum Ltd
Aspirin Cuts Liver Fat in Preliminary MASLD Trial
medpagetoday.com
To view or add a comment, sign in
9,615 followers